Indeed, currently there is only one FDA-approved ctDNA based mutation test but only for the detection of EGFR mutations in NSCLC patients: the Cobas EGFR Mutation Test v2 (Cobas EGFR Mutation Test v2. Here, EGFR is linked to non-small cell lung carcinoma.